Compare Crispr Therapeutics AG (CRSP) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs 10X Genomics Inc — how do they compare? Crispr Therapeutics AG trades at $54.09 (market cap $5.22B), while 10X Genomics Inc trades at $58.73 (market cap $7.52B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | TXG | |
|---|---|---|
Market Cap | $5.22B | $7.52B |
Sector | Health | Health |
52-Week High | $76.78 | $58.57 |
52-Week Low | $44.34 | $11.34 |
Enterprise Value | $3.64B | $7.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.99, down 0.15% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by 151% YoY growth in CASGEVY sales to $76 million. Financials show deep losses with a net income margin of -4,101.26% in 2025, though cash flow improved to a net positive $49.30M. Recent news highlights strong analyst optimism and pipeline advancements.
Outlook remains speculative with high growth potential from gene-editing therapies like CASGEVY, but significant risks persist from ongoing losses and clinical trial outcomes. Wall Street consensus is bullish with a $82.67 price target, implying 53% upside, though investors face volatility from earnings misses and cash burn.
TXG trades at $58.15, down 0.5% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q2 2026 earnings beating estimates, with revenue of $151 million and a loss per share of $0.14 versus an expected $0.24 loss. Gross margin improved to 70.03%, and cash flow from operations strengthened to $136 million in 2025. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook is mixed: analyst consensus is a Hold with a $48.38 price target below current levels, indicating caution despite recent earnings beats. Risks include persistent net losses, high valuation multiples like a P/S of 11.95, and competitive pressures in life sciences. Institutional activity shows mixed signals, with some firms increasing stakes while others reduce holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
